Sanofi Pasteur MSD's shingles vaccine now available in France
Shingles vaccine Zostavax from Sanofi Pasteur MSD, the vaccines joint venture of French drug major Sanofi (Euronext: SAN) and US pharma giant Merck & Co (NYSE: MRK), is now available across France, with national reimbursement for adults aged 65 to 74.
Zostavax is recommended for shingles, also known as zoster, and its most common related complication, chronic nerve pain. In addition to the 65 to 74 age range, catch-up for adults aged 75 to 79 is available until the end of February 2017.
Jean-Paul Kress, president of Sanofi Pasteur MSD, said: "The availability of Zostavax in France is an important step forward in the prevention of zoster and its complication offering to a broader number of senior Europeans the chance of protection from this serious and debilitating disease. Sanofi Pasteur MSD is committed to preventative health care at all ages and the Zostavax zoster vaccine is a key enabler to secure lifelong immunization for healthier lives.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze